Browsing by Author "Guler, O. C."
Now showing 1 - 20 of 42
- Results Per Page
- Sort Options
Item Adjuvant Small Pelvic Radiation Therapy in Cervical Cancer Patients With Minor Risk Factors(2016) Sari, S. Yuce; Guler, O. C.; Gultekin, M.; Onal, C.; Yildiz, F.; 0000-0001-6908-3412; ABX-1273-2022; AAC-5654-2020; HOC-5611-2023Item Automatic Prediction of Metastasis-Free Survival (MFS) Using Prostate-Specific Membrane Antigen (PSMA) PET for Oligometastatic Castration-Sensitive Prostate Cancer (omCSPC)(2023) Cao, Y.; Sutera, P.; Mendes, W.; Yousefi, B.; Hrinivich, W. T.; Deek, M. P.; Phillips, R.; Song, D.; Kiess, A. P.; Guler, O. C.; Torun, N.; Reyhan, M.; Tran, P. T.; Ona, H. C.; Rent, L.; 37784389Item The Clinical Outcomes Of Breast Cancer Lung Metastasis Treated With Stereotactic Body Radiotherapy(2022) Guler, O. C.; Sari, S. Yuce; Gultekin, M.; Yildiz, F.; Onal, C.Item Comparison of IMRT and VMAT Plans with Different Energy Levels Using Monte Carlo Algorithm for Prostate Cancer(2014) Guler, O. C.; Onal, C.; Arslan, G.; Sonmez, S.; HOC-5611-2023Item The Correlation Between FDG-PET Parameters and Hematologic Parameters in Patients with Esophageal Squamous-Cell Carcinoma Treated with Definitive Chemoradiotherapy(2017) Yildirim, B. Akkus; Onal, C.; Torun, N.; Ozdemir, Y.; Guler, O. C.; 0000-0001-6661-4185; 0000-0002-5597-676X; 0000-0002-2218-2074; 0000-0001-6908-3412; V-5717-2017; HOC-5611-2023; AAE-2718-2021; AAG-5629-2021; AAC-5654-2020Item The Dosimetric Analysis & Clinical Outcomes of Contiguous Vertebrae SBRT in Oligometastatic Patients(2022) Guler, O. C.; Oymak, E.; Onal, C.Item Dosimetric Comparison of Simultaneous-Integrated BOOST and Sequential BOOST with VMAT or Helical Tomotherapy in Breast Cancer Patients after Breast-Conserving Surgery(2019) Onal, C.; Efe, E.; Yildirim, B. Akkus; Guler, O. C.; 0000-0001-6908-3412; AAC-5654-2020Item The Effect of ADT on ADC Change in Intermediate-Risk Prostate Cancer Patients Receiving Radiotherapy(2023) Onal, C.; Erbay, G.; Oymak, E.; Guler, O. C.; 0000-0002-1706-8680; AAK-5370-2021Item The Effect Of Bladder Volume On Three-Dimensional Vaginal Cuff Brachytherapy Planning(2022) Birgi, S. Duru; Guler, O. C.; Babayigit, Y.; Arslan, Y.; Akyurek, S.; GZH-1201-2022Item The Effect of the Time Interval between Temozolomide and Radiotherapy in Adjuvant High-Grade Glioma Treatment(2022) Oymak, E.; Demircan, V.; Senyurek, S.; Yavas, G.; Guler, O. C.; Bolukbasi, Y.; Erpolat, P.; Onal, C.Item The Feasibility of Prostate-Specific Membrane Antigen Positron Emission Tomography(PSMA PET/CT)-Guided Radiotherapy in Oligometastatic Prostate Cancer Patients(2018) Guler, O. C.; Engels, B.; Onal, C.; Everaert, H.; Van den Begin, R.; Gevaert, T.; de Ridder, M.; https://orcid.org/0000-0001-6908-3412; https://orcid.org/0000-0001-9108-610X; https://orcid.org/0000-0002-2742-9021; https://orcid.org/0000-0003-3633-6203; https://orcid.org/0000-0003-4556-5681; https://orcid.org/0000-0003-4433-8807; 28795303; AAC-5654-2020; HOC-5611-2023; B-1285-2018; F-3248-2016; F-4794-2013To investigate the efficacy and toxicity of 68Ga-PSMA-HBED-CC (Ga-68-PSMA) PET-CT-guided RT in the treatment of oligometastatic prostate cancer retrospectively. A total of 23 prostate cancer patients with biochemical relapse, of which 13 were castration sensitive (CS) and 10 castration resistant (CR), were treated with intensity-modulated and image-guided RT (IMRT-IGRT) on 3 metastases detected by Ga-68 PSMA PET-CT. Androgen deprivation therapy was continued in CR patients. A total of 38 metastases were treated. The involved sites were pelvic bone (n = 16), pelvic lymph nodes (n = 11), paraaortic lymph nodes (n = 6), ribs (n = 3) and vertebral body (n = 2). The median PSA prior to RT was 1.1 ng/mL (range 0.1-29.0 ng/mL). A median dose of 43.5 Gy (range 30-64 Gy) was delivered by IMRT-IGRT in 12-27 fractions. At a median follow-up of 7 months (range 2-17 months), 19 patients (83%) were in remission. Four patients (17%) developed distant recurrences. The actuarial 1-year LC, PFS and OS rates were 100, 51 (95% CI 8-83%) and 100%. Univariate analysis demonstrated a statistically significantly better PFS in CS patients as compared to CR patients (1-year PFS 67 vs. 0%, p < 0.01). One patient experienced grade 2 acute gastrointestinal toxicity. Grade 3 or more toxicity events were not observed. By providing optimal LC, low toxicity and a promising PFS in CS patients, the current retrospective study illustrated that Ga-68 PSMA PET-CT-guided RT may be an attractive treatment strategy in patients with oligometastatic prostate cancer. Validation by randomized trials is eagerly awaited.Item The impact of lymph node ratio in patients with stage IIIC endometrial carcinoma(2021) Onal, C.; Sari, S. Yuce; Yavas, G.; Guler, O. C.; Yigit, E.; Oymak, E.; Gultekin, M.; Yildiz, F.Item The Impact of Suvmax for Evaluation of Treatment Response in Esophageal Carcinoma Patients Treated with Definitive Chemoradiotherapy(2015) Onal, C.; Guler, O. C.; Yildirim, B. A.; Torun, N.; 0000-0001-6661-4185; 0000-0001-6908-3412; 0000-0002-5597-676X; V-5717-2017; AAC-5654-2020; HOC-5611-2023; AAE-2718-2021Item The Impact of the ADC for the Early Prediction of Treatment Response After Definitive Radiotherapy(2023) Onal, C.; Erbay, G.; Guler, O. C.; Oymak, E.; 0000-0002-1706-8680; AAK-5370-2021Item The Impact of Tumor Volume in Breast Cancer Liver Metastasis Patients Treated with Stereotactic Radiotherapy - Does Size Matter?(2020) Guler, O. C.; Yildirim, B. Akkus; Onal, C.; 0000-0002-2742-9021; 0000-0001-6908-3412; D-5195-2014; AAC-5654-2020Item The Importance of Positron Emission Tomography Parameters in Esophageal Carcinoma Treated with Radiotherapy(2015) Onal, C.; Guler, O. C.; Yildirim, B. A.; Torun, N.; 0000-0002-5597-676X; 0000-0001-6661-4185; 0000-0001-6908-3412; HOC-5611-2023; AAE-2718-2021; V-5717-2017; AAC-5654-2020Item The Importance of Prognostic Nutritional Index in Cervical Cancer Patients Treated with Concomitant Chemoradiotherapy(2017) Yildirim, B. Akkus; Guler, O. C.; Onal, C.; 0000-0001-6661-4185; 0000-0001-6908-3412; V-5717-2017; AAC-5654-2020; HOC-5611-2023Item Long-term Outcomes of Cervical Cancer Patients Treated With Definitive Chemoradiation Following a Complete Metabolic Response(2021) Onal, C.; Oymaki, E.; Guler, O. C.; 33906779Item National, Observational, Multicentric Retrospective Study to Understand Treatment Patterns, Patient Journey and Characteristics with Stage III Non-Small Cell Lung Cancer Patients in Turkey: Stone Trial(2020) Onal, C.; Demiral, A.N.; Atalar, B.; Yalman, D.; Dagoglu, R.N.; Hurmuz, P.; Erpolat, P.; Akyurek, S.; Gul, S. Karabulut; Berber, T.; Guler, O. C.; Umay, C.; Sert, F.; Saglam, E.K.; Eray, K.; Birgi, S. Duru; Yaprak, G.; 0000-0002-2742-9021; 0000-0001-6908-3412; D-5195-2014; AAC-5654-2020; HOC-5611-2023Item The Outcomes of Definitive Radiotherapy in Patients with Prostate Cancer Using Simultaneous Integrated Boost Technique(2022) Onal, C.; Guler, O. C.; Erbay, G.; Oymak, E.; Yavas, C.; Yavas, G.; 0000-0002-1706-8680; AAK-5370-2021
- «
- 1 (current)
- 2
- 3
- »